CN110709066A - 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法 - Google Patents

含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法 Download PDF

Info

Publication number
CN110709066A
CN110709066A CN201880035839.5A CN201880035839A CN110709066A CN 110709066 A CN110709066 A CN 110709066A CN 201880035839 A CN201880035839 A CN 201880035839A CN 110709066 A CN110709066 A CN 110709066A
Authority
CN
China
Prior art keywords
indirubin
solvent
dihydro
indole
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035839.5A
Other languages
English (en)
Chinese (zh)
Inventor
吴斌
P·布歇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phosphorex Inc
Original Assignee
Phosphorex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosphorex Inc filed Critical Phosphorex Inc
Priority to CN202310039510.9A priority Critical patent/CN115969814A/zh
Publication of CN110709066A publication Critical patent/CN110709066A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880035839.5A 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法 Pending CN110709066A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310039510.9A CN115969814A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478317P 2017-03-29 2017-03-29
US62/478,317 2017-03-29
PCT/US2018/025075 WO2018183631A1 (en) 2017-03-29 2018-03-29 Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310039510.9A Division CN115969814A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Publications (1)

Publication Number Publication Date
CN110709066A true CN110709066A (zh) 2020-01-17

Family

ID=63676834

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880035839.5A Pending CN110709066A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法
CN202310039510.9A Pending CN115969814A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310039510.9A Pending CN115969814A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Country Status (7)

Country Link
US (3) US20200016087A1 (https=)
EP (1) EP3600259A4 (https=)
JP (2) JP2020515598A (https=)
CN (2) CN110709066A (https=)
AU (1) AU2018244442A1 (https=)
CA (1) CA3058407A1 (https=)
WO (1) WO2018183631A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法
CN115569133A (zh) * 2020-02-26 2023-01-06 上海科技大学 甲异靛在抗冠状病毒中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855423B1 (ko) * 2017-04-18 2018-05-09 주식회사 씨케이바이오텍 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물
WO2020214855A1 (en) * 2019-04-17 2020-10-22 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
CN114521142B (zh) * 2019-11-04 2024-07-02 Ck雷容股份有限公司 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
EP4329747A4 (en) * 2021-04-29 2025-03-19 Jawaharlal Nehru Centre For Advanced Scientific Research SOLUBLE ANALOGUES OF 6 BIO, AND THEIR IMPLEMENTATION
EP4412991A1 (en) 2021-10-08 2024-08-14 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550206A (zh) * 2013-10-23 2014-02-05 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
CN106029065A (zh) * 2013-12-20 2016-10-12 法斯瑞斯公司 靛玉红固体分散组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004285522A1 (en) * 2003-10-28 2005-05-12 Centre National De La Recherche Scientifique Indirubin-type compounds, compositions, and methods for their use
WO2012012616A1 (en) * 2010-07-21 2012-01-26 Patty-Fu Giles Photoactive vitamin nanoparticles for the treatment of chronic wounds
US9193954B2 (en) * 2011-03-31 2015-11-24 University Of Rochester Methods and compositions for mesenchymal stem cell proliferation
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
US9707186B2 (en) * 2012-02-21 2017-07-18 Amrita Vishwa Vidyapeetham Core-shell particle formulation for delivering multiple therapeutic agents
ES2685743T3 (es) * 2012-02-29 2018-10-11 Merck Patent Gmbh Procedimiento para la fabricación de nanopartículas cargadas con principio activo
CN110123763A (zh) * 2012-06-21 2019-08-16 法斯瑞斯公司 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
EP2878312A1 (en) * 2013-12-02 2015-06-03 Albert-Ludwigs-Universität Freiburg Reversible PEGylation of nanocarriers
WO2016197262A1 (en) * 2015-06-12 2016-12-15 Bayer Pharma Aktiengesellschaft Process for the preparation of porous microparticles
JP2018523702A (ja) * 2015-08-17 2018-08-23 フォスフォレックス，インコーポレイテッド 分解性ポリマーの極小ナノ粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550206A (zh) * 2013-10-23 2014-02-05 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
CN106029065A (zh) * 2013-12-20 2016-10-12 法斯瑞斯公司 靛玉红固体分散组合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
RUI FANG ET AL: "Sustained co-delivery of BIO and IGF-I by a novel hybrid hydrogeI system to stimulate endoge nous cardiac repair in myocardial infarcted rat hearts", 《INTERNATIONAL JOURNAL OF NANOMEDICINE》 *
YAN WANG ET AL: "Synthesis of Biodegradable Poly(butylenes terephthalate)/poly(ethylene glycol) (PBT/PEG) Multiblock Copolymers and Preparation of IndirubinLoaded Microspheres", 《POLYMER BULLETIN》 *
梅兴国主编: "《微载体药物递送系统》", 30 November 2009, 华中科学技术出版社 *
郑俊民主编: "《药用高分子材料学》", 31 January 2009, 中国医药出版社 *
马瑞: "《生物学前沿技术在医学研究中的应用》", 30 September 2007, 复旦大学出版社 *
高焕民等: "《纳米医学》", 31 May 2006, 军事医学科学出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115569133A (zh) * 2020-02-26 2023-01-06 上海科技大学 甲异靛在抗冠状病毒中的应用
CN115569133B (zh) * 2020-02-26 2024-04-26 上海科技大学 甲异靛在抗冠状病毒中的应用
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Also Published As

Publication number Publication date
AU2018244442A1 (en) 2019-10-24
EP3600259A4 (en) 2020-11-25
CN115969814A (zh) 2023-04-18
JP2020515598A (ja) 2020-05-28
US20200383931A1 (en) 2020-12-10
WO2018183631A8 (en) 2019-08-15
JP2023040147A (ja) 2023-03-22
US20200016087A1 (en) 2020-01-16
CA3058407A1 (en) 2018-10-04
EP3600259A1 (en) 2020-02-05
US20230100193A1 (en) 2023-03-30
WO2018183631A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CN110709066A (zh) 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法
JP6878398B2 (ja) Ｐａｒｐ阻害剤固形医薬剤型及びその使用
KR102168263B1 (ko) 주사 제제
ES2741447T3 (es) Tratamientos contra enfermedad autoinmune
JP2003026607A (ja) 薬剤と濃度を高めるポリマーとを含む医薬組成物
CN101426477A (zh) 纳米颗粒卡维地洛制剂
Xu et al. RVG-functionalized reduction sensitive micelles for the effective accumulation of doxorubicin in brain
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
Panda et al. RETRACTED: Self-assembled phenylalanine-α, β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor
CN108601793B (zh) 使用5′-腺苷二磷酸核糖(adpr)的方法
JP2013151574A (ja) チューブリンインヒビターであるインジブリン（Ｉｎｄｉｂｕｌｉｎ）の改良された薬物動態学を有する、経口投与のための薬剤組成物、及びその製造法
KR101741344B1 (ko) 피페라진 화합물의 나노미립자 조성물 및 제제
CN104274401A (zh) 一种基于hcpt-peg的喜树碱类药物的高载药纳米混悬剂及其制备方法
US20170014383A1 (en) Solid dispersion of indirubin
KR20120094178A (ko) 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
US20080213385A1 (en) Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
CN110384803B (zh) 一种大环主体分子作为药物增溶剂的应用
ES2845639T3 (es) Forma cristalina de 6-[(4R)-4-metil-1,2-dióxido-1,2,6-tiadiazinan-2-il]isoquinolin-1-carbonitrilo
CN118766866A (zh) 改善治疗剂的溶解度和生物利用度的方法
WO2024211881A1 (en) Rimegepant suspension
CN116370409A (zh) 司替戊醇纳米混悬液、纳米胶束及其制备方法与应用
HK1132903A (en) Nanoparticulate carvedilol formulations
JP2019515029A (ja) アイバカフトールならびにアイバカフトールの塩及び誘導体の複合剤、その製造方法ならびにこれを含有する医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200117

RJ01 Rejection of invention patent application after publication